Challenges of providing care to adults with cystic fibrosis

European Respiratory Monograph

Volumn 64, Issue , 2014, Pages 286-303

  Bell, Scott C ^a,b,c   Reid, David W ^a,c,d  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b Queensland Children's Medical Research Institute   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; AZTREONAM; IVACAFTOR; MACROLIDE; TOBRAMYCIN;

ACHROMOBACTER XYLOSOXIDANS; ARTERY EMBOLISM; ARTICLE; BACTERIAL INFECTION; BODY MASS; BURKHOLDERIA CENOCEPACIA; CHILD PARENT RELATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE ERADICATION; DRUG HYPERSENSITIVITY; EMPLOYMENT STATUS; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LUNG FUNCTION; LUNG TRANSPLANTATION; MENTAL HEALTH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIUM; NONHUMAN; NUTRITIONAL STATUS; PATIENT CARE; PATIENT COMPLIANCE; PATIENT HEALTH QUESTIONNAIRE 9; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOTHORAX; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; SELF CARE; SOCIAL MEDIA; SURVIVAL RATE;

EID: 84905726464     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10010513     Document Type: Article

References (146)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373: 1891-904.
2. European Cystic Fibrosis Patient Registry Annual Data Report 2008-2009. Karup, European Cystic Fibrosis Society, 2012.
3. Canadian Cystic Fibrosis Registry 2011 Annual Report. Toronto, Cystic Fibrosis Canada, 2012.
4. Cystic Fibrosis Foundation Patient Registry. 2012 Annual Data Report. Bethesda, Cystic Fibrosis Foundation, 2013.
5. UKCF Registry Annual Data Report 2011. London, Cystic Fibrosis Trust, 2013.
6. th Annual Report from the Cystic Fibrosis Data Registry. Sydney, Cystic Fibrosis Australia, 2013.
7. Port CFNZ 2012 National Data Registry. Auckland, Cystic Fibrosis Association of New Zealand, 2013.
8. Nick JA, Chacon CS, Brayshaw SJ, et al. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Critical Care Med 2010; 182: 614-626.
9. Nick JA, Rodman DM. Manifestations of cystic fibrosis diagnosed in adulthood. Curr Opin Pulm Med 2005; 11: 513-518.
10. Rodman DM, Reese K, Harral J, et al. Low-voltage-activated (T-type) calcium channels control proliferation of human pulmonary artery myocytes. Circ Res 2005; 96: 864-872.
11. Simmonds NJ, D'Souza L, Roughton M, et al. Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function. Eur Respir J2011; 37: 1076-1082.
12. Collaco JM, McGready J, Green DM, et al. Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study. PLoS One 2011; 6: e27784.
13. Collaco JM, Morrow CB, Green DM, et al. Environmental allergies and respiratory morbidities in cystic fibrosis. Pediatr Pulmonol 2013; 48: 857-864.
14. Green DM, Collaco JM, McDougal KE, et al. Heritability of respiratory infection withPseudomonas aeruginosain cystic fibrosis. J Pediatr 2012; 161: 290-295.
15. Schechter MS. Nongenetic influences on cystic fibrosis outcomes. Curr Opin Pulm Med 2011; 17: 448-454.
16. Schechter MS, McColley SA, Regelmann W, et al. Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. J Pediatr 2011; 159: 819-824.
17. Batten J. Cystic fibrosis: a review. Br J Dis Chest 1965; 59: 1-9.
18. Conway SP, Stableforth DE, Webb AK. The failing health care system for adult patients with cystic fibrosis. Thorax 1998; 53: 3-4.
19. Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J2007; 29: 522-526.
20. McCormick J, Mehta G, Olesen HV, et al. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet 2010; 375: 1007-1013.
21. Gutierrez HH, Sanchez I, Schidlow DV. Cystic fibrosis care in Chile. Curr Opin Pulm Med 2009; 15: 632-637.
22. Macri CN, de Gentile AS, Manterola A, et al. Epidemiology of cystic fibrosis in Latin America: preliminary communication. Pediatr Pulmonol 1991; 10: 249-253.
23. Simmonds NJ, Cullinan P, Hodson ME. Growing old with cystic fibrosis-the characteristics of long-term survivors of cystic fibrosis. Respir Med 2009; 103: 629-635.
24. Plant BJ, Goss CH, Plant WD, et al. Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med 2013; 1: 164-174.
25. Flume PA, Strange C, Ye X, et al. Pneumothorax in cystic fibrosis. Chest 2005; 128: 720-728.
26. Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest 2005; 128: 729-738.
27. Brinson GM, Noone PG, Mauro MA, et al. Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med 1998; 157: 1951-1958.
28. Hodson ME, Simmonds NJ, Warwick WJ, et al. An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J Cyst Fibros 2008; 7: 537-542.
29. Burrows JA, Nissen LM, Kirkpatrick CM, et al. Beta-lactam allergy in adults with cystic fibrosis. J Cyst Fibros 2007; 6: 297-303.
30. Whitaker P, Naisbitt D, Peckham D. Nonimmediate beta-lactam reactions in patients with cystic fibrosis. Curr Opin Allergy Clin Immunol 2012; 12: 369-375.
31. Catherinot E, Roux AL, Vibet MA, et al. Mycobacterium aviumandMycobacterium abscessuscomplex target distinct cystic fibrosis patient subpopulations. J Cyst Fibros 2013; 12: 74-80.
32. Leung JM, Olivier KN. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013; 34: 124-134.
33. Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak ofMycobacterium abscessussubspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012; 185: 231-232.
34. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission ofMycobacterium abscessusbetween patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381: 1551-1560.
35. Nick JA, Moskowitz SM, Chmiel JF, et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosain cystic fibrosis. Ann Am Thorac Soc 2014; 11: 342-350.
36. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
37. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected withPseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-1756.
38. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212-216.
39. Moran A, Becker D, Casella SJ, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosisrelated diabetes: a technical review. Diabetes Care 2010; 33: 2677-83.
40. Moran A, Dunitz J, Nathan B, et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32: 1626-1631.
41. Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros 2013; 12: 318-331.
42. Burrows JA, Toon M, Bell SC. Antibiotic desensitization in adults with cystic fibrosis. Respirology 2003; 8: 359-364.
43. Whitaker P, Shaw N, Gooi J, et al. Rapid desensitization for non-immediate reactions in patients with cystic fibrosis. J Cyst Fibros 2011; 10: 282-285.
44. Quon BS, Mayer-Hamblett N, Aitken ML, et al. Risk of post-lung transplant renal dysfunction in adults with cystic fibrosis. Chest 2012; 142: 185-189.
45. Quon BS, Mayer-Hamblett N, Aitken ML, et al. Risk factors for chronic kidney disease in adults with cystic fibrosis. Am J Respir Crit Care Med 2011; 184: 1147-1152.
46. Florescu MC, Lyden E, Murphy PJ, et al. Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis. Hemodial Int 2012; 16: 414-419.
47. O'Connell OJ, Harrison MJ, Murphy DM, et al. Peri-lung transplant renal issues in patients with cystic fibrosis. Chest 2013; 143: 271.
48. Mulrennan SA, Helm J, Thomas RB, et al. Aminoglycoside ototoxicity susceptibility in cystic fibrosis. Thorax 2009; 64: 271-272.
49. O'Donnell EP, Scarsi KK, Scheetz MH, et al. Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients. Int J Antimicrob Agents 2010; 36: 94-95.
50. France MW, Bell SC. Gastrointestinal cancers in cystic fibrosis. CML Cystic Fibrosis 2014; 4: 1-14.
51. Garwood S, Flume PA, Ravenel J. Superior vena cava syndrome related to indwelling intravenous catheters in patients with cystic fibrosis. Pediatr Pulmonol 2006; 41: 683-687.
52. Meyer KC, Francois ML, Thomas HK, et al. Colon cancer in lung transplant recipients with CF: increased risk and results of screening. J Cyst Fibros 2011; 10: 366-369.
53. Nash EF, Helm EJ, Stephenson A, et al. Incidence of deep vein thrombosis associated with peripherally inserted central catheters in adults with cystic fibrosis. J Vasc Interv Radiol 2009; 20: 347-351.
54. Rhodes B, Nash EF, Tullis E, et al. Prevalence of dyslipidemia in adults with cystic fibrosis. J Cyst Fibros 2010; 9: 24-28.
55. Maisonneuve P, Fitz-Simmons SC, Neglia JP, et al. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst 2003; 95: 381-387.
56. Maisonneuve P, Marshall BC, Knapp EA, et al. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst 2013; 105: 122-129.
57. Coderre L, Fadainia C, Belson L, et al. LDL-cholesterol and insulin are independently associated with body mass index in adult cystic fibrosis patients. J Cyst Fibros 2012; 11: 393-397.
58. Macnee W, Maclay J, McAllister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 824-833.
59. Hull JH, Garrod R, Ho TB, et al. Increased augmentation index in patients with cystic fibrosis. Eur Respir J2009; 34: 1322-1328.
60. Hull JH, Garrod R, Ho TB, et al. Dynamic vascular changes following intravenous antibiotics in patients with cystic fibrosis. J Cyst Fibros 2013; 12: 125-129.
61. Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med 2005; 171: 1053-1059.
62. Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166: 1550-1555.
63. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187-1191.
64. George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ2011; 342: d1008.
65. Bradbury RA, Shirkhedkar D, Glanville AR, et al. Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an "orphan" area? A retrospective case-control study. Intern Med J 2009; 39: 384-388.
66. Hofer M, Schmid C, Benden C, et al. Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation. J Cyst Fibros 2012; 11: 131-136.
67. Emerson J, McNamara S, Buccat AM, et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010; 45: 363-370.
68. Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepaciacomplex: results from two French centres. Thorax 2008; 63: 732-737.
69. De Soyza A, Meachery G, Hester KL, et al. Lung transplantation for patients with cystic fibrosis andBurkholderia cepaciacomplex infection: a single-center experience. J Heart Lung Transplant 2010; 29: 1395-1404.
70. Aris RM, Gilligan PH, Neuringer IP, et al. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155: 1699-1704.
71. Braun AT, Merlo CA. Cystic fibrosis lung transplantation. Curr Opin Pulm Med 2011; 17: 467-472.
72. Doring G, Flume P, Heijerman H, et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012; 11: 461-479.
73. Hadjiliadis D, Steele MP, Chaparro C, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other thanBurkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007; 26: 834-838.
74. Hirche TO, Knoop C, Hebestreit H, et al. Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med 2014; 2014: 621342.
75. Edenborough FP, Borgo G, Knoop C, et al. Guidelines for the management of pregnancy in women with cystic fibrosis. J Cyst Fibros 2008; 7: Suppl. 1, S2-S32.
76. Thorpe-Beeston JG, Madge S, Gyi K, et al. The outcome of pregnancies in women with cystic fibrosis-single centre experience 1998-2011. BJOG2013; 120: 354-361.
77. Tonelli MR, Aitken ML. Pregnancy in cystic fibrosis. Curr Opin Pulm Med 2007; 13: 537-540.
78. Whitty JE. Cystic fibrosis in pregnancy. Clin Obstet Gynecol 2010; 53: 369-376.
79. Goss CH, Rubenfeld GD, Otto K, et al. The effect of pregnancy on survival in women with cystic fibrosis. Chest 2003; 124: 1460-1468.
80. McMullen AH, Pasta DJ, Frederick PD, et al. Impact of pregnancy on women with cystic fibrosis. Chest 2006; 129: 706-711.
81. Schechter MS, Quittner AL, Konstan MW, et al. Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis. Ann Am Thorac Soc 2013; 10: 213-219.
82. Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009; 361: 1339-1348.
83. Corey M, McLaughlin FJ, Williams M, et al. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988; 41: 583-591.
84. U. S. Food and Drug Administration. FDA approves Kalydeco to treat rare form of cystic fibrosis. www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm289633. htmDate last updated: January 31, 2012. Date last accessed: April 17, 2014.
85. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013; 187: 1219-1225.
86. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672.
87. Besier T, Born A, Henrich G, et al. Anxiety, depression, and life satisfaction in parents caring for children with cystic fibrosis. Pediatr Pulmonol 2011; 46: 672-682.
88. Cruz I, Marciel KK, Quittner AL, et al. Anxiety and depression in cystic fibrosis. Semin Respir Crit Care Med 2009; 30: 569-578.
89. Goldbeck L, Besier T, Hinz A, et al. Prevalence of symptoms of anxiety and depression in German patients with cystic fibrosis. Chest 2010; 138: 929-936.
90. Latchford G, Duff AJ. Screening for depression in a single CF centre. J Cyst Fibros 2013; 12: 794-796.
91. Riekert KA, Bartlett SJ, Boyle MP, et al. The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. Chest 2007; 132: 231-237.
92. Yohannes AM, Willgoss TG, Fatoye FA, et al. Relationship between anxiety, depression, and quality of life in adult patients with cystic fibrosis. Respir Care 2012; 57: 550-556.
93. Kopp BT, Wang W, Chisolm DJ, et al. Inpatient healthcare trends among adult cystic fibrosis patients in the U. S. Pediatr Pulmonol 2012; 47: 245-251.
94. Besier T, Goldbeck L. Growing up with cystic fibrosis: achievement, life satisfaction, and mental health. Qual Life Res 2012; 21: 1829-1835.
95. Abbott J, Dodd M, Gee L, et al. Ways of coping with cystic fibrosis: implications for treatment adherence. Disabil Rehabil 2001; 23: 315-324.
96. Segal TY. Adolescence: what the cystic fibrosis team needs to know. J R Soc Med 2008; 101: Suppl. 1, S15-S27.
97. Bury M. The sociology of chronic illness: a review and prospects. Sociol Health Illn 1991; 13: 451-468.
98. Collins S, Reynolds F. How do adults with cystic fibrosis cope following a diagnosis of diabetes?J Adv Nurs 2008; 64: 478-487.
99. Lowton K, Gaby J. Life on a slippery slope: perception of health in adults with cystic fibrosis. Sociol Health Illn 2003; 25: 289-319.
100. Watson H, Bilton D, Truby H. A randomized controlled trial of a new behavioral home-based nutrition education program, "Eat Well with CF, " in adults with cystic fibrosis. J Am Diet Assoc 2008; 108: 847-852.
101. Stark LJ, Opipari-Arrigan L, Quittner AL, et al. The effects of an intensive behavior and nutrition intervention compared to standard of care on weight outcomes in CF. Pediatr Pulmonol 2011; 46: 31-35.
102. Duff AJ, Latchford GJ. Motivational interviewing for adherence problems in cystic fibrosis. Pediatr Pulmonol 2010; 45: 211-220.
103. Duff AJ, Latchford GJ. Motivational interviewing for adherence problems in cystic fibrosis; evaluation of training healthcare professionals. J Clin Med Res 2013; 5: 475-480.
104. Quinn J, Latchford G, Duff A, et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatr Pulmonol 2004; 38: S360.
105. Roehrer E, Cummings E, Turner P, et al. Supporting cystic fibrosis with ICT. Stud Health Technol Inform 2013; 183: 137-141.
106. Sawicki GS, Sellers DE, McGuffie K, et al. Adults with cystic fibrosis report important and unmet needs for disease information. J Cyst Fibros 2007; 6: 411-416.
107. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease selfmanagement. J Cyst Fibros 2009; 8: 91-96.
108. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 105-116.
109. Eakin MN, Bilderback A, Boyle MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011; 10: 258-264.
110. Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J2012; 40: 61-66.
111. Daniels T, Goodacre L, Sutton C, et al. Accurate assessment of adherence: self-report and clinician reportvs electronic monitoring of nebulizers. Chest 2011; 140: 425-432.
112. Eakin MN, Riekert KA. The impact of medication adherence on lung health outcomes in cystic fibrosis. Curr Opin Pulm Med 2013; 19: 687-691.
113. Finney JW, Hook RJ, Friman PC, et al. The overestimation of adherence to pediatric medical regimens. Child Health Care 1993; 22: 297-304.
114. Burker EJ, Sedway J, Carone S. Psychological and educational factors: better predictors of work status than FEV1in adults with cystic fibrosis. Pediatr Pulmonol 2004; 38: 413-418.
115. Saldana PS, Pomeranz JL. Cystic fibrosis and the workplace: a review of the literature. Work 2012; 42: 185-193.
116. Taylor-Robinson DC, Smyth R, Diggle PJ, et al. A longitudinal study of the impact of social deprivation and disease severity on employment status in the UK cystic fibrosis population. PLoS One 2013; 8: e73322.
117. Targett K, Bourke S, Nash E, et al. Employment in adults with cystic fibrosis. Occup Med (Lond)2014; 64: 87-94.
118. Bullough B. Poverty, ethnic identity and preventive health care. J Health Soc Behav 1972; 13: 347-359.
119. Duncan GJ, Brooks-Gunn J. Family poverty, welfare reform, and child development. Child Dev 2000; 71: 188-196.
120. Wagstaff A. Poverty and health sector inequalities. Bull World Health Organ 2002; 80: 97-105.
121. Ullrich G. Employment in CF adults deserves much more attention. J Cyst Fibros 2013; 12: 416.
122. Demars N, Uluer A, Sawicki GS. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil 2011; 33: 922-926.
123. Lowton K. Only when I cough? Adults' disclosure of cystic fibrosis. Qual Health Res 2004; 14: 167-186.
124. Modi AC, Quittner AL, Boyle MP. Assessing disease disclosure in adults with cystic fibrosis: the Adult Data for Understanding Lifestyle and Transitions (ADULT) survey Disclosure of disease in adults with cystic fibrosis. BMC Pulm Med 2010; 10: 46.
125. Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK (2nd edn). London, Cystic Fibrosis Trust, 2011.
126. Colombo C, Littlewood J. The implementation of standards of care in Europe: state of the art. J Cyst Fibros 2011; 10: Suppl. 2, S7-S15.
127. Kerem E, Conway S, Elborn S, et al. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005; 4: 7-26.
128. Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125: 1S-39S.
129. Marciel KK, Saiman L, Quittell LM, et al. Cell phone intervention to improve adherence: cystic fibrosis care team, patient, and parent perspectives. Pediatr Pulmonol 2010; 45: 157-164.
130. Cummings E, Borycki EM, Roehrer E. Issues and considerations for healthcare consumers using mobile applications. Stud Health Technol Inform 2013; 183: 227-231.
131. Roehrer E, Cummings E, Beggs S, et al. Pilot evaluation of web enabled symptom monitoring in cystic fibrosis. Inform Health Soc Care 2013; 38: 354-365.
132. Bella S, Cotognini C, Alghisi F, et al. Program of home telemonitoring in patients with cystic fibrosis over a period of 2 years: a contribution to the rationalization of care. Clin Ter 2013; 164: e313-e317.
133. Cox NS, Alison JA, Rasekaba T, et al. Telehealth in cystic fibrosis: a systematic review. J Telemed Telecare 2012; 18: 72-78.
134. Murgia F, Cilli M, Renzetti E, et al. Remote telematic control in cystic fibrosis. Clin Ter 2011; 162: e121-e124.
135. Ledger SJ, Owen E, Prasad SA, et al. A pilot outreach physiotherapy and dietetic quality improvement initiative reduces IV antibiotic requirements in children with moderate-severe cystic fibrosis. J Cyst Fibros 2013; 12: 766-772.
136. Thomas C, Mitchell P, O'Rourke P, et al. Quality-of-life in children and adolescents with cystic fibrosis managed in both regional outreach and cystic fibrosis center settings in Queensland. J Pediatr 2006; 148: 508-516.
137. Thomas CL, O'Rourke PK, Wainwright CE. Clinical outcomes of Queensland children with cystic fibrosis: a comparison between tertiary centre and outreach services. Med J Aust 2008; 188: 135-139.
138. Britton LJ, Thrasher S, Gutierrez H. Creating a culture of improvement: experience of a pediatric cystic fibrosis center. J Nurs Care Qual 2008; 23: 115-120.
139. Chuang S, Doumit M, McDonald R, et al. Annual review clinic improves care in children with cystic fibrosis. J Cyst Fibros 2014; 13: 186-189.
140. Homa K, Sabadosa KA, Nelson EC, et al. Development and validation of a cystic fibrosis patient and family member experience of care survey. Qual Manag Health Care 2013; 22: 100-116.
141. Kern AS, Prestridge AL. Improving screening for cystic fibrosis-related diabetes at a pediatric cystic fibrosis program. Pediatrics 2013; 132: e512-e518.
142. Quon BS, Goss CH. A story of success: continuous quality improvement in cystic fibrosis care in the USA. Thorax 2011; 66: 1106-1108.
143. Schechter MS. Benchmarking to improve the quality of cystic fibrosis care. Curr Opin Pulm Med 2012; 18: 596-601.
144. Stern M, Niemann N, Wiedemann B, et al. Benchmarking improves quality in cystic fibrosis care: a pilot project involving 12 centres. Int J Qual Health Care 2011; 23: 349-356.
145. Steinkamp G, Stahl K, Ullrich G, et al. CF Care through the patients' eyes: development of a disease specific questionnaire measuring patient satisfaction with CF services. J Cyst Fibros 2010; 9: S100.
146. Cox NS, Alison JA, Button BM, et al. Assessing exercise capacity using telehealth: a feasibility study in adults with cystic fibrosis. Respir Care 2013; 58: 286-290.